Repurposing Cancer Drug to Treat Alzheimer’s in Those With Genetic Risk Factors

This shows a brainDasatinib, an FDA-approved drug for chronic myeloid leukemia, and an experimental drug for liver cancer reduced neuroinflammation, tau phosphorylation, and amyloid secretion in cell cultures of post-mortem brain samples of those with the APOE4 Alzheimer’s associated gene.